-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Eliem Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2020 to Q2 2024.
- Eliem Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$54.9M, a 952% decline year-over-year.
- Eliem Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$64.2M, a 42.8% decline year-over-year.
- Eliem Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$35.1M, a 22.4% increase from 2022.
- Eliem Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$45.2M, a 4.71% increase from 2021.
- Eliem Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$47.5M, a 130% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)